The U.S. Food and Drug Administration accepted Mineralys Therapeutics’ New Drug Application for lorundrostat, the company’s lead candidate for uncontrolled hypertension. The acceptance sets a Prescription Drug User Fee Act target action date of December 22 2026, giving the company a clear regulatory timeline for a potential approval decision.
In the Phase 2 Explore‑OSA trial, 48 patients with moderate‑to‑severe obstructive sleep apnea and hypertension were enrolled. The study found no reduction in the apnea‑hypopnea index, but lorundrostat produced a clinically meaningful 11.1 mmHg drop in systolic blood pressure and a 6.2 mmHg placebo‑adjusted reduction in a crossover analysis. The average baseline apnea‑hypopnea index was 48.5 events per hour and the mean baseline systolic blood pressure was 142.3 mmHg. No patient experienced serum potassium elevations above 5.5 mmol/L, underscoring the drug’s favorable safety profile.
The FDA acceptance and the Explore‑OSA data advance Mineralys’s strategy to bring a differentiated aldosterone synthase inhibitor to market. Lorundrostat’s selective inhibition of CYP11B2 reduces aldosterone production without the anti‑androgenic side effects of mineralocorticoid receptor antagonists, positioning it to address the unmet need for patients with uncontrolled or resistant hypertension, a population that often overlaps with obstructive sleep apnea. The trial’s blood‑pressure benefit, even in the absence of an apnea‑hypopnea improvement, suggests the drug could still provide therapeutic value for this difficult‑to‑treat cohort.
Jon Congleton, Mineralys’s chief executive officer, said, “The FDA’s acceptance of our NDA for lorundrostat marks an important milestone in our efforts to address the clinically significant need faced by millions of patients living with uncontrolled or resistant hypertension.” He added, “While the Explore‑OSA trial did not demonstrate a reduction in AHI, the blood pressure reductions and safety profile were clinically meaningful, especially for this difficult to control population. We believe lorundrostat has the potential to become an important new treatment option for resistant and uncontrolled hypertension, and we look forward to working with the FDA as we advance toward potential approval.”
Mineralys remains a clinical‑stage biopharmaceutical company with no revenue and ongoing losses, but it has a sizable cash runway that mitigates near‑term funding risk. The company has completed five Phase 2/3 trials for lorundrostat, including the pivotal Launch‑HTN and Advance‑HTN studies, which support its efficacy and safety profile in hypertension.
The drug’s potential market extends beyond hypertension alone. Because obstructive sleep apnea is an independent risk factor for hypertension, patients with both conditions represent a sizable U.S. patient segment that could benefit from a therapy that lowers blood pressure without compromising sleep‑apnea severity. In a market that includes other aldosterone synthase inhibitors such as baxdrostat, lorundrostat’s distinct mechanism and safety profile may give it a competitive edge as the class expands.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.